Generic versions of Lipitor to hit pharmacy shelves

NewsGuard 100/100 Score

In just days, a number of generic versions of Lipitor will hit pharmacy shelves. Pfizer's 180-day generic exclusivity agreement for the medication expires at the end of the month. That will bring a host of new generic alternatives, and potential confusion, to more than 3 million Americans looking to control their cholesterol and reduce the cost of their drug therapies.

Clark Kebodeaux, Pharm.D., assistant professor pharmacy practice at St. Louis College of Pharmacy, deals with this issue every day when he's practicing at Walgreens in St. Louis.

He will answer some common questions including:
•Will the price of Lipitor come down?
•Will the new generic alternatives work as well as Lipitor?
•Does the generic medication affect me differently?
•Do the inactive ingredients in the medication have any effect on patients?
•Are there cases where the brand name works better than the generic?
•Questions patients should ask their pharmacist or doctor about switching to generic.

Lipitor is the best-selling prescription drug of all time, and most prescribed brand-name drug in America. Every day about 3.5 million Americans take Lipitor.

Source:

 St. Louis College of Pharmacy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights variable use and rising costs of antivirals in treating pediatric influenza in the U.S.